Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -5.44% is 80% above its 5-year average of -27.49%, near the high end of its 5-year range (-54.12%–-4.22%).
81.35% above its 12-month average of -29.17%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -4.35%.
RETURN ON ASSETS (ROA)
-5.44%
RETURN ON ASSETS (ROA) AVG TTM
-29.17%
RETURN ON ASSETS (ROA) AVG 3Y
-28.46%
RETURN ON ASSETS (ROA) AVG 5Y
-27.49%
RETURN ON ASSETS (ROA) AVG 10Y
-18.30%
RETURN ON ASSETS (ROA) AVG 15Y
-21.79%
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+81.35%
CURRENT VS 3Y AVG
+80.89%
CURRENT VS 5Y AVG
+80.21%
CURRENT VS 10Y AVG
+70.28%
CURRENT VS 15Y AVG
+75.03%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+83.13%
vs the sector median at left
Travere Therapeutics, Inc.
Market Cap
$5.18B
Return on Assets (ROA)
-5.44%
TTM Avg
-29.17%
3Y Avg
-28.46%
5Y Avg
-27.49%
Market Cap
$5.16B
Return on Assets (ROA)
-45.20%
TTM Avg
-56.55%
3Y Avg
-55.28%
5Y Avg
-47.01%
Market Cap
$5.21B
Return on Assets (ROA)
4.94%
TTM Avg
1.92%
3Y Avg
-0.50%
5Y Avg
0.13%
Market Cap
$5.15B
Return on Assets (ROA)
-78.04%
TTM Avg
-72.67%
3Y Avg
-59.05%
5Y Avg
-50.29%
Market Cap
$5.25B
Return on Assets (ROA)
-17.02%
TTM Avg
-21.01%
3Y Avg
-19.47%
5Y Avg
-13.88%
Market Cap
$5.25B
Return on Assets (ROA)
15.41%
TTM Avg
17.55%
3Y Avg
14.67%
5Y Avg
15.71%
Market Cap
$5.05B
Return on Assets (ROA)
5.08%
TTM Avg
4.88%
3Y Avg
4.58%
5Y Avg
3.44%
Market Cap
$5.34B
Return on Assets (ROA)
-1.18%
TTM Avg
1.12%
3Y Avg
-15.90%
5Y Avg
-18.41%
Market Cap
$5.01B
Return on Assets (ROA)
2.30%
TTM Avg
0.76%
3Y Avg
-0.18%
5Y Avg
-0.34%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | $5.18B | -5.44% | -29.17% | -28.46% | -27.49% |
| Cogent Biosciences, Inc. (COGT)vs › | $5.16B | -45.20% | -56.55% | -55.28% | -47.01% |
| Sotera Health Company (SHC)vs › | $5.21B | 4.94% | 1.92% | -0.50% | 0.13% |
| Scholar Rock Holding Corporation (SRRK)vs › | $5.15B | -78.04% | -72.67% | -59.05% | -50.29% |
| CRISPR Therapeutics AG (CRSP)vs › | $5.25B | -17.02% | -21.01% | -19.47% | -13.88% |
| Doximity, Inc. (DOCS)vs › | $5.25B | 15.41% | 17.55% | 14.67% | 15.71% |
| Merit Medical Systems, Inc. (MMSI)vs › | $5.05B | 5.08% | 4.88% | 4.58% | 3.44% |
| PTC Therapeutics, Inc. (PTCT)vs › | $5.34B | -1.18% | 1.12% | -15.90% | -18.41% |
| Waystar Holding Corp. (WAY)vs › | $5.01B | 2.30% | 0.76% | -0.18% | -0.34% |
| Erasca, Inc. (ERAS)vs › | $4.95B | -66.02% | -31.80% | -35.60% | -41.38% |
ROA
-5.4%
ROE
-177.2%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -4.22% |
| 2024-12-31 | -54.12% |
| 2023-12-31 | -14.12% |
| 2022-12-31 | -41.40% |
| 2021-12-31 | -23.19% |
| 2020-12-31 | -27.89% |
| 2019-12-31 | -24.21% |
| 2018-12-31 | -14.48% |
| 2017-12-31 | -11.48% |
| 2016-12-31 | -9.12% |
| 2015-12-31 | 22.88% |
| 2014-12-31 | -81.89% |
| 2013-12-31 | -165.00% |
| 2012-12-31 | -1268.95% |
| 2012-02-29 | -379.25% |
| 2011-02-28 | 0.00% |
| 2010-02-28 | 0.00% |
| 2009-02-28 | -382.85% |
